Trial Profile
Phase 1/2 Study of Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Lenalidomide (Primary)
- Indications Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 22 Dec 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2009-013423-31).
- 25 Jul 2012 Status changed from recruiting to discontinued as reported by EudraCT.
- 28 Jul 2010 New trial record